邮箱: qrding@sinh.ac.cn
电话: +86-21-54920998
所属部门: 营养代谢与食品安全重点实验室
2017-至 今：中国科学院上海营养与健康研究所 研究员
2014-2016年：中国科学院上海生命科学研究院营养科学研究所 研究员
2010-2014年：美国哈佛大学干细胞研究所、干细胞与转化生物学系 博士后
2004-2010年：中国科学院上海生命科学研究院营养科学研究所 博士
2000-2004年：南京大学生物科学系 学士
多能干细胞与肝脏疾病
1. 基于人多能干细胞的疾病研究和靶向治疗
利用患者来源的诱导性多能干细胞（iPSC）或者体外建立的疾病胚胎干细胞（ESC），结合基因编辑和定向分化平台，在功能基因组水平研究人类肝脏疾病的分子机理，发现新型靶标；发展基于干细胞疾病模型的药物筛选和毒理评价体系；进行药物化合物筛选，研发针对特定靶标的药物先导化合物；优化体外多能干细胞肝向分化平台，建立肝脏异种嵌合动物模型，探索基于人多能干细胞来源的肝脏细胞作为肝移植潜在肝源的可行性。
2. 肝脏脂代谢紊乱的遗传及表观遗传基础
结合干细胞疾病模型、基因编辑在体大规模筛选和人群疾病遗传学分析，研究肝脏脂代谢紊乱及其导致的肝再生能力下降的遗传和表观遗传基础，探索预防和治疗包括脂肪肝、肝纤维化等肝病的方法和手段。
3. 代谢疾病的基因治疗研究
针对高甘油三酯血症、高胆固醇血症、肿瘤恶病质等代谢疾病，以CRISPR/Cas9在体靶向技术为基础，筛选新型靶标，优化基因治疗方案，开展临床前研究。
1. Tian C#*, Guo X#, Wang D, Chen Q, Shen H, Li X, Liu C, Qi Y, Chen Y, Wang L,Wang Y, Cao Y, Liu Y, Yin H, Chen Y, Gu X, Jiang C*, Tang L*, Xie C*, Ding Q*. Uric acid promotes dietary lipid absorption through microbiome and metabolomic remodeling via a liver-gut endocrine axis. Cell Host Microbe. 2026. Jun 3:S1931-3128(26)00181-2. doi: 10.1016/j.chom.2026.05.005.
2. Zhang Y, Wang Y, Li B, Li X, Liu C, Chen Y, Tian C, Wang D, Gu X, Jiang C*, Wei Y*, Ding Q*. Selenoprotein H Functions as a PPARα Coactivator to Link Selenium Homeostasis to Hepatic Lipid Metabolism and Protect against Steatohepatitis. Adv Sci (Weinh). 2026. 13(22):e19563.
3. Jiang D, Wang Y, Chen Y, Tian C, Li X, Li S, Gu X, Jiang C*, Ding Q*.Mitochondrial Pyruvate Carrier Differentially Controls the Self-Renewal and Differentiation of Human Pluripotent Stem Cells. J Cell Physiol. 2025. 240(8):e70083.
4. Qi Y, He X, Wu X, Zhou T, Liang N, Jiao J, Chen Y, Yuan Y, Zhang Y, Wang Y, Liu Y, Ding Q*. Identification of deferasirox as a human xanthine oxidase inhibitor. Life Med. 2025. 4(2): Inaf014.
5. Tian C, Gu X, Jiang C*, Ding Q*. Emerging roles of MRG15 in liver metabolic diseases. Trends Mol Med. 2024. 30(6):527-529.
6. Li S#, Jiang D#, Li X, Zhao Y, Gu X, Jiang C*, Ding Q*. CD157 selectively identifies hPSCs with enhanced hepatic differentiation capacity. Life Med. 2024. Inae 026.
7. Wu X, Jiang D, Wang Y, Li X, Liu X, Chen Y, Sun W, He R, Yang Y, Gu X, Jiang C*, Ding Q*. Modeling metabolic-associated steatohepatits with human pluripotent stem cell-derived liver organoids. Hepatol Commun. 2024. 8(12):e0585.
8. Chen Y#*, Chen L#, Wu X#, Zhao Y, Wang Y, Jiang D, Liu X, Zhou T, Li S, Wei Y, Liu Y, Hu C, Zhou B, Qin J, Ying H, Ding Q*. Acute liver steatosis translationally controls the epigenetic regulator MIER1 to promote liver regeneration in a study with male mice. Nat Commun. 2023. 14(1):1521.
9. Zhao Y#*, Li S#, Chen Y, Wang Y, Wei Y, Zhou T, Zhang Y, Yang Y, Chen L, Liu Y, Hu C, Zhou B, Ding Q*. Histone phosphorylation integrates the hepatic glucagon-PKA-CREB gluconeogenesis program in response to fasting. Mol Cell 2023. S1097-2765(23)00102-8. doi: 10.1016/j.molcel.2023.02.007.
10. Wu X, Jiang D, Li S*, Ding Q*. Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids. Cell Regen. 2023. 12(1):6. doi: 10.1186/s13619-022-00148-1.
11. Zhou T, Musunuru K, Lui K*, Ding Q*. Decoding liver fibrogenesis with single-cell technologies. Life Med. 2022. Inac040.
12. Tian C, Min X, Zhao Y, Wang Y, Wu X, Liu S, Dou W, Zhou T, Liu Y, Luo R, Li Z, Lui KO, Li Y, Zhou B, Ding Q*. MRG15 aggravates non-alcoholic steaohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM. J Hepatol. 2022. S0168-8278(22)02981-6.
13. Han J#*, Wang Y#*, Qiu Y, Sun D, Liu Y, Li Z, Zhou B, Zhang H, Xiao Y, Wu G*, Ding Q*. Single-cell sequencing unveils key contributions of immune cell populations in cancer-associated adipose wasting. Cell Discov. 2022. 8(1):122.
14. Chen Y, Ding Q*. Optimized protocols for efficient gene editing in mouse hepatocytes in vivo using CRISPR-Cas9 technology. STAR Protoc. 2022. 3(1): 101062.
15. Qiu Y, Ding Q*. Optimized protocol for gene editing in adipocytes using CRISPR-Cas9 technology. STAR Protoc. 2021. 2: 100307.
16. Qiu Y, Liu X, Sun Y, Zeng X, Li S, Wei Y, Tian C, Ding Q*. In situ saturating mutagenesis screening identifies a functional genomic locus that regulates Ucp1 expression. Phenomics 2020.1:15-21.
17. Liu X, Yang Y, Qiu Y, Md. Reyad-ul-ferdous, Ding Q*, Wang Y*. SeqCor: correct the effect of gRNA sequences in CRISPR/Cas9 screenings by machine learning algorithm. J Genet Genomics. 2020. 47: 672-680.
18. Qiu Y, Yang Y, Wei Y, Liu X, Feng Z, Zeng X, Chen Y, Liu Y, Zhao Y, Chen L, Luo L, Ding Q*. Glyburide regulates UCP1 expression in adipocytes independent of K ATP channel blockade. iScience 2020; 23: 101446.
19. Ding Q*. Spotlight on gene therapy in China. Gene Ther. 2020; 27: 307-308.
20. Wei Y#, Tian C#, Zhao Y#, Liu X, Liu F, Li S, Chen Y, Qiu Y, Feng Z, Chen L, Zhou T, Ren X, Feng C, Liu Y, Yu W, Ying H, Ding Q*. MRG15 orchestrates rhythmic epigenomic remodeling and controls hepatic lipid metabolism. Nat Metab. 2020; 2:447-460.
21. Yang Y#, Liu X#, Li S, Chen Y, Zhao Y, Wei Y, Qiu Y, Liu Y, Zhou Z, Han J*, Wu G*, Ding Q*. Genome-scale CRISPR screening for potential targets of ginsenoside compound K. Cell Death Dis. 2020. 11: 39.
22. Zhao Y#, Feng Z#, Ding Q*. Type 2 Diabetes Variants in the SLC16A11 coding region are not loss-of-function mutations. Cell Rep. 2019. 29:1-4.
23. Feng Z, Wei Y, Zhang Y, Qiu Y, Liu X, Su L, Liang N, Yin H, Ding Q*. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression. Theranostics 2019. 9: 3501-3514.
24. Zhao Y#, Feng Z#, Zhang Y#, Sun Y, Chen Y, Liu X, Li S, Zhou T, Chen L, Wei Y, Ma D, Lui K, Ying H, Chen Y, Ding Q*. Gain-of-function mutations of SLC16A11 contribute to the pathogenesis of type 2 diabetes. Cell Rep. 2019. 26:884-892.
25. Qiu Y#, Sun Y#, Xu D, Yang Y, Liu X, Wei Y, Chen Y, Feng Z, Li S, Ferdous M, Zhao Y, Xu H, Lao Y*, Ding Q*. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue. EBioMedicine 2018. 37:344-355.
26. Li S, Li M, Liu X, Yang Y, Wei Y, Chen Y, Qiu Y, Zhou T, Feng Z, Ma D, Fang J, Ying H, Wang H, Musunuru K, Shao S*, Zhao Y*, Ding Q*. Genetic and chemical screenings identify HDAC3 as a key regulator in hepatic differentiation of human pluripotent stem cells. Stem Cell Rep. 2018. 11:22-31.
27. Sun Y, Ding Q*. Genome engineering of stem cell organoids for disease modeling. Protein Cell 2017. 8:315-327.
28. Wei Y, Qiu Y, Chen Y, Liu G, Zhang Y, Xu L, Ding Q*. CRISPR/Cas9 with single guide RNA expression driven by small tRNA promoters showed reduced editing efficiency compared to U6 promoter. RNA 2017. 23:1-5.
29. Wei Y, Chen Y, Qiu Y, Zhao H, Liu G, Zhang Y, Meng Q, Wu G, Chen Y, Cai X, Wang H, Ying H, Zhou B, Liu M, Li D, Ding Q*. Prevention of muscle wasting by CRISPR/Cas9-mediated disruption of myostatin in vivo. Mol Ther. 2016. 24: 1889-91.
30. Chen Y, Liu X, Zhang Y, Wang H, Ying H, Liu M, Li D, Lui K, Ding Q*. A Self- restricted CRISPR System to Reduce Off- target Effects. Mol Ther. 2016. 24: 1508-10.
31. Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q*, Musunuru K*. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo. Arterioscler Thromb Vasc Biol. 2016. 143: 1475-81.
官方微信
